We are grateful for the results from Dr. Rodríguez et al. supporting our previous article.1 We agree with their conclusion that a combination assay of CYFRA 21-1 with carcinoembryonic antigen (CEA) and CA 15-3 is very useful for breast carcinoma, since the epitope of CYFRA 21-1 is a polypeptide whereas those of CEA and CA 15-3 are glycoproteins. We are particularly interested in the prognostic value of CYFRA 21-1 for disease recurrence after surgery. We now routinely measure CYFRA 21-1 for our patients with breast carcinoma prior to operation and at serial times after operation. Some patients with abnormal serum CYFRA 21-1 titers have maintained elevated levels of the marker after curative resection. These patients may have high risk of the disease relapse. The coming data from Dr. Rodríguez et al. will contribute to a followup system for patients with breast carcinoma.